About Edge Therapeutics
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize, hospital-based therapies capable of transforming treatment paradigms in the management of life-threatening neurological and other conditions. Edge is evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). This study will evaluate EG-1962's ability to improve patient outcomes versus standard of care oral nimodipine after an aSAH resulting from a ruptured brain aneurysm. Edge's product candidates utilize Precisa, a platform with a approach that seeks to enable targeted and sustained drug exposure at the site of injury, while potentially avoiding off-target side effects associated with systemic delivery. Edge is also using its Precisa development platform to develop additional product candidates targeting other acute, serious conditions where limited or no current therapies exist.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: EDGE
- Previous Close: $10.00
- 50 Day Moving Average: $10.50
- 200 Day Moving Average: $10.80
- 52-Week Range: $6.52 - $13.50
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.27
- P/E Growth: -0.08
- Market Cap: $291.77M
- Outstanding Shares: 28,917,000
- Beta: 2.83
- Return on Equity: -33.77%
- Return on Assets: -30.43%
Companies Related to Edge Therapeutics:
- Debt-to-Equity Ratio: 0.15%
- Current Ratio: 26.62%
- Quick Ratio: 26.62%
What is Edge Therapeutics' stock symbol?
Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."
Where is Edge Therapeutics' stock going? Where will Edge Therapeutics' stock price be in 2017?
3 analysts have issued 12-month price objectives for Edge Therapeutics' stock. Their forecasts range from $18.00 to $24.00. On average, they anticipate Edge Therapeutics' stock price to reach $20.00 in the next year.
When will Edge Therapeutics announce their earnings?
Edge Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
Who owns Edge Therapeutics stock?
Edge Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (8.73%), New Leaf Venture Partners L.L.C. (8.11%), Janus Capital Management LLC (7.48%), Acuta Capital Partners LLC (3.60%), Opaleye Management Inc. (0.97%) and FMR LLC (0.72%). Company insiders that own Edge Therapeutics stock include Andrew J Einhorn, Brian A Leuthner, James Healy and W Bradford Middlekauff.
Who sold Edge Therapeutics stock? Who is selling Edge Therapeutics stock?
Edge Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC.
Who bought Edge Therapeutics stock? Who is buying Edge Therapeutics stock?
Edge Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including New Leaf Venture Partners L.L.C., Acuta Capital Partners LLC, Franklin Resources Inc. and State Street Corp. Company insiders that have bought Edge Therapeutics stock in the last two years include Andrew J Einhorn, James Healy and W Bradford Middlekauff.
How do I buy Edge Therapeutics stock?
Shares of Edge Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Edge Therapeutics stock cost?
One share of Edge Therapeutics stock can currently be purchased for approximately $10.09.